Is 5-Amino-1MQ a peptide?

No. Despite being sold by peptide vendors, 5-Amino-1MQ is a small molecule — an NNMT (nicotinamide N-methyltransferase) inhibitor of about 159 daltons, with no amino-acid chain. It's grouped with peptides only because that's where it's marketed. This matters for sourcing and quality standards.

How does 5-Amino-1MQ cause fat loss?

It inhibits NNMT, an enzyme overexpressed in fat cells that promotes fat storage and consumes NAD+. Blocking it shifts fat cells from storing toward burning fat and raises intracellular NAD+. In rodent studies this reduced fat mass and improved insulin sensitivity without the animals eating less — a metabolic redirection, not appetite suppression.

Is 5-Amino-1MQ as effective as semaglutide or tirzepatide?

No, and it's frequently mismarketed that way. GLP-1 compounds are substantially more effective for meaningful weight loss. 5-Amino-1MQ is best understood as a supporting metabolic and body-recomposition compound, often paired with other approaches — not a primary weight-loss tool.

Is there human data on 5-Amino-1MQ?

No human clinical trials exist. The evidence is preclinical — rodent obesity models — plus community experience. Human dosing is extrapolated, not validated, which is an important limitation to understand before use.

5-Amino-1MQ — Research Profile

Name: 5-Amino-1MQ — Research Profile
Creator: Dr. Scott DelBoccio, DMD

The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.

View the Index →

Why This Page Exists

Interesting mechanism, oversold marketing

5-Amino-1MQ has a genuinely clever mechanism and a genuinely thin evidence base, and the market ignores both halves — selling it as a peptide (it isn't) and as a GLP-1 alternative (it isn't). The real story: it inhibits an enzyme called NNMT that's overexpressed in fat cells and aging tissue, which redirects fat metabolism and preserves NAD+. That's mechanistically elegant. It's also entirely preclinical in humans. Both facts belong on the same page.

In one sentence5-Amino-1MQ is an oral NNMT inhibitor that shifts fat cells from storing toward burning and raises NAD+ — a supporting metabolic compound, not a primary weight-loss drug, with no human trial data.

Regulatory & Classification

What it is — and isn't

United States — FDA

Research Compound · Not Approved

Not FDA-approved for any use. All data is preclinical (rodent models); human dosing is extrapolated.

Classification

Small Molecule — Not a Peptide

A ~159 Da quinolinium compound with no amino-acid chain. Sold by peptide vendors, but chemically and practically not a peptide — which changes sourcing and quality expectations.

Route

Orally Active

Can be taken orally — a real convenience advantage over injectables. (Some reference protocols also list an injectable form; the two routes differ in bioavailability.)

WADA

Verify Independently

Not explicitly prohibited as of recent lists, but metabolic-modulator categories may apply — athletes should confirm.

Mechanism of Action

How 5-Amino-1MQ works

It inhibits NNMT — the "fat-storage" enzyme

NNMT (nicotinamide N-methyltransferase) is overexpressed in adipose tissue and aging cells. When overactive, it promotes fat storage and burns through nicotinamide, lowering NAD+. Inhibiting it releases both brakes at once.

5-Amino-1MQ → ↓ NNMT → fat cells shift storage → oxidation · ↑ intracellular NAD+

It redirects fat metabolism without touching appetite

The landmark rodent finding: NNMT inhibition reduced fat mass and improved insulin sensitivity without the animals eating less. This is metabolic redirection — the opposite of how GLP-1s work (which suppress appetite). It doesn't affect ghrelin or the central nervous system.

It raises NAD+ by a different route than precursors

Rather than feeding NAD+ precursors in (like NR or NMN), it stops NNMT from consuming them. The downstream effects overlap with direct NAD+ support — energy metabolism, DNA repair, sirtuin activation — which is why it also carries a longevity angle.

How it differs from the other fat-loss tools

Unlike GLP-1s (appetite) or AOD-9604 (direct lipolysis), 5-Amino-1MQ works at the enzymatic regulatory level of fat-cell behavior. That's why it's positioned as complementary to those compounds, not a replacement for them.

Primary Use Cases

What 5-Amino-1MQ is discussed for

Body recomposition & stubborn fat
The primary use — a supporting compound for resistant or visceral fat, often alongside a GLP-1 or GH-axis protocol rather than alone.
Metabolic health / insulin sensitivity
Improved insulin sensitivity in preclinical models, without appetite suppression — appealing where metabolic optimization is the goal.
NAD+ elevation
An indirect NAD+ strategy — blocking consumption rather than adding precursors; complementary to or partially overlapping with direct NAD+ support.
Longevity / anti-aging (adjacent)
NNMT is overexpressed in aging tissue, making its inhibition a longevity-adjacent mechanism — early and mechanistic, not proven.

Positioning, stated plainlyThis is a premium, secondary compound — a metabolic and recomposition partner, not a primary weight-loss agent. For meaningful weight loss, GLP-1 compounds are substantially more effective. Anyone marketing 5-Amino-1MQ as a GLP-1 equivalent is overselling it.

Evidence Summary

What the research shows — and its limits

Basis	Type	Key finding
Rodent obesity models (Kraus, Neelakantan et al.)	Preclinical	NNMT inhibition reduced fat mass and improved insulin sensitivity without reduced food intake.
NAD+ / metabolic mechanism	Preclinical	NNMT inhibition preserves intracellular NAD+, supporting sirtuin activity and energy metabolism.
Community / biohacker experience	Anecdotal	Subtle fat-reduction and energy effects reported at 3–6 weeks; far milder than GLP-1s.
Human clinical trials	—	None. All human dosing is extrapolated from animal data.

Evidence strength

Mechanism (NNMT / NAD+)

Preclinical-solid

Fat loss (animal)

Preclinical

Human effectiveness

Unproven

As a GLP-1 substitute

Not supported

Protocols

Dosing consensus

Educational reference only — no human trials establish dosing, and cycling is advised to maintain NNMT responsiveness.

Oral — community range≈ 50–150 mg daily

The dominant real-world format. Taken in the morning, fasted, ideally pre-cardio to align with fat oxidation.

Injectable — reference protocol≈ 2.5 mg, 4× weekly

A lower-exposure injectable protocol also exists; note the two routes differ substantially in bioavailability, so oral and injectable doses are not interchangeable.

Cycling8 weeks on / 4 off (standard)

Cycling preserves enzyme responsiveness; best evaluated over a full 8-week block, since effects are subtle.

Red Flags & Cautions

Where 5-Amino-1MQ needs care

No human clinical trials. All efficacy and safety data is from rodents; human use is extrapolation.
Not a peptide — sourcing differs. Different synthesis and quality standards than peptides; the oral-capsule market is uneven, so a certificate of analysis matters.
Overstated marketing. Frequently sold as a GLP-1 equivalent. It isn't — expectations set that high lead to disappointment.
Cardiovascular disease. Caution advised in a CVD context.
Pregnancy / breastfeeding. Avoid — no safety data.

Common Questions

5-Amino-1MQ questions answered

Is it a peptide?

No — it's a small molecule (~159 Da) with no amino-acid chain. It's an NNMT inhibitor sold by peptide vendors, which is why it gets grouped with peptides, but chemically it's a different class. That distinction affects how it's sourced and quality-tested.

How is it different from taking NMN or NR for NAD+?

NMN and NR add NAD+ precursors into the system. 5-Amino-1MQ instead stops the enzyme (NNMT) that consumes them — raising NAD+ from the other direction. Some people view them as complementary rather than either/or.

Will it replace my GLP-1?

No. GLP-1 compounds are far more effective for meaningful weight loss. 5-Amino-1MQ is a supporting metabolic and recomposition compound — useful alongside a primary approach, not as a stand-in for one.

How fast does it work?

Slowly and subtly. Community reports describe noticeable fat and energy changes around 3–6 weeks, best judged over a full 8-week cycle. If you're expecting GLP-1-style results, you'll be disappointed — the mechanism is different and milder.

Related Research

Weight loss & metabolic hub

About the Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and metabolic medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every profile is an independent synthesis of the primary literature, evidence-graded and corrected in the open. No products are sold on this site.

Full Disclaimer

5-Amino-1MQ (5-amino-1-methylquinolinium) is not approved by the U.S. Food and Drug Administration for any indication and is a research compound with no human clinical trials; it is a small molecule, not a peptide. Information on this page is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. Human dosing is extrapolated from preclinical data. It is not a substitute for FDA-approved weight-management medicines. Any use should be under the supervision of a qualified physician. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory classifications continue to evolve.